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a  b  s  t  r  a  c  t
Curcumin  (CUR)  is  a highly  pleiotropic  molecule  and  possesses  anti-inﬂammatory,  hypo-
glycemic,  antioxidative,  wound-healing  and  antimicrobial  activities.  The  present  study  was
carried  out  to investigate  whether  CUR  plays  any  beneﬁcial  role in  streptozotocin  (STZ)
induced  hepatic  pathophysiology  in diabetic  rats. STZ  exposure  increased  hepatic  damage
associated  serum  markers  (ALT, ALP  and  LDH)  as well  as  NO  production  in the liver tissue.
Moreover,  the  same  exposure  enhanced  ROS  generation  and  lipid  peroxidation;  reduced
GSH  levels  and  antioxidant  enzyme  activities.  Hyperglycemia  induced  hepatic  pathophy-
siology  also  activated  stress  response  pathways  (involving  phosphorylation  of  p38,  ERK1/2




lular apoptosis  as  evidenced  from  increased  hepatic  DNA  fragmentation  as  well  as FACS
analysis.  However,  treatment  with  CUR  effectively  counteracts  diabetes-induced,  oxidative
stress mediated  hepatic  damage  and  could  act as  a therapeutic  in  lessening  liver  dysfunction
in diabetic  subjects.
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1. Introduction
Diabetes is the most common endocrine disorder
now-a-days. It is basically a group of metabolic dis-
eases characterized by hyperglycemia and resulting from
the defects in insulin secretion, insulin action or both
[1]. Hyperglycemia contributes to the progression and
maintenance of overall oxidative environment. Increasing
evidence from both the experimental and clinical stud-
ies indicates that oxidative stress plays a major role in
the diabetic pathophysiology [2]. Reactive oxygen species
(ROS) are generated disproportionately in diabetes by var-
ious pathways [3]. Among these various pathways, high
glucose (and also other sugars) activates the polyol path-
way, increased formation of AGEs (advanced glycation
end products) along with the expression of the receptor
for AGEs, activation of protein kinase C (PKC) isoforms
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and increased activity of the hexosamine pathway were
reported to be important [4]. ROS usually damage dif-
ferent organs of the body by peroxidation of membrane
lipids, oxidation of proteins, DNA and other intracellular
macromolecules. Changes in oxidative stress biomarkers,
including glutathione, superoxide dismutase, catalase, glu-
tathione reductase, glutathione peroxidase, some vitamins
and associated genes may  serve as a quantitative measure-
ment of oxidative damage in diabetes [5]. Our aim was
to ﬁnd out easily available and inexpensive antioxidant
molecules which can effectively reduce hepatic oxidative
overload under diabetic conditions. For this purpose we
have chosen curcumin, a commonly used foodstuff and an
important component of Indian herbal medicine. Curcumin
is a diaryl heptanoid and is the principal curcuminoid
of the popular South Asian spice, turmeric. It is a well-
known antioxidant [6] and highly pleiotropic molecule that
has been reported to exert a wide range of pharmaco-
logical activities like antibacterial [7] anti-inﬂammatory,
anti-cancer, anti-oxidant [8], hypoglycaemic [9,10], anti-
atherosclerotic, anti-microbial [10], wound healing [11],
etc. Moreover, curcumin has been found to interact directly
with various intracellular signalling molecules [12]. Its
ameliorative effects have been indicated to be medi-
ated through the modulation of multiple cell signalling
molecules like apoptotic proteins, cyclooxygenase (COX)-
2, NF-B [13], STAT3, IKK, interleukin [IL]-1, IL-6 [14],
endothelin-1, C-reactive protein (CRP) [15], GST [16,17],
PSA, pro-inﬂammatory cytokines (tumour necrosis factor
[TNF]- [18], VCAM, prostaglandin E2, malondialdehyde
(MDA), glutathione (GSH) [19], pepsinogen, phosphory-
lase kinase (PhK) [20], creatinine, transferrin receptor, total
cholesterol, transforming growth factor (TGF)-,  triglyc-
eride, HO-1 [21], etc. Most importantly, curcumin has been
reported to have the capacity to directly scavenge ROS [22].
We have done a thorough search in the literature related
to the beneﬁcial effects of curcumin on diabetic rat liver.
All the research articles published so far focuses mainly on
curcumin’s beneﬁcial roles on the biochemical parameters
[23,24]. Some recent reports also described other beneﬁcial
roles of curcumin against generalized diseased conditions;
like its antioxidant effect [6], anti-diabetic effect [25], etc.
Some of the structural analogues of curcumin were also
investigated for the similar effects ([26]; [42]). However,
detail mechanism was not carried out in any of those
studies related to our experimental model. In our study,
we have performed a detailed mechanistic investigation
to assess not only the biochemical changes but also the
molecular signalling pathways through which curcumin
exert its beneﬁcial effects. In the present study, we have
investigated the protective action of curcumin, like in the
enhancement of the activity of antioxidant enzymes (usu-
ally thought to be the ﬁrst line of cellular defence against
oxidative damage); elevation of the body weight; increase
in the cellular antioxidant power (FRAP); elevation of cel-
lular non-enzymatic antioxidant (GSH) content; increase
in the mitochondrial membrane potential ( m); ame-
lioration of the tissue damage (histological assessment)
and most importantly, inhibition of p53 and p38-ERK1/2
MAPKs mediated mitochondrial Bax translocation and
subsequent intrinsic mitochondrial apoptotic pathway inorts 2 (2015) 365–376
diabetes-induced hepatic oxidative stress. The outcome of
this study could help to determine the role of this bioac-
tive molecule in reducing diabetes induced oxidative stress
and might shed some light on the darkness of the gradual
deterioration of this serious endocrine disorder worldwide.
2. Materials and methods
2.1. Materials
2.1.1. Chemicals
Curcumin, STZ, BSA, Bradford reagent, anti-Bcl-2, anti-
Bcl-XL, anti-Bad and anti-Bax antibodies were purchased
from Abcam (UK). Other antibodies like anti-ERK, anti-p53,
etc. were purchased from Sigma–Aldrich Chemical Com-
pany (St. Louis, MO,  USA). Kits for measurement of blood
glucose and LDH were purchased from Span Diagnostic Ltd.,
India. All other chemicals were bought from Sisco Research
Laboratory, India.
2.1.2. Animals
Adequate numbers of adult male Wistar rats weighing
approximately 220–280 g were purchased from M/S Gosh
Enterprises, Kolkata, India. All the animals were acclima-
tized under laboratory conditions for 2 weeks before any
experiment. Animals were maintained under standard con-
ditions of temperature (23 ± 2 ◦C) and humidity (50 ± 10%)
with alternating 12 h light/dark cycle. The animals were
given free access to tap water and fed standard pellet diet
(Agro Corporation Private Ltd., Bangalore, India). All the
experiments involving animals were carried out according
to the guidelines of the Institutional Animal Ethical Com-
mittee (IAEC), Bose Institute, Kolkata (the permit number
is IAEC/BI/3(I) cert./2010) and full details of the study was
approved by both IAEC and Committee for the Purpose of
Control and Supervision on Experiments on Animals (CPC-
SEA), Ministry of Environment & Forests, New Delhi, India
(the permit number is 95/99/CPCSEA).
2.2. Methods
2.2.1. Experimental design for in vivo treatments
Experimental design needed for the present in vivo
study has been summarized as follows: Rats were ran-
domly assigned to four groups and treated as follows:
Group 1: Normal group: rats received neither STZ nor cur-
cumin, received vehicle only.
Group 2: CUR group: rats received only CUR (100 mg/kg
body weight in olive oil) orally for 56 days (simultaneously
with Group 4).
Group 3: STZ group: rats received single dose of STZ (STZ,
60 mg/kg body weight in citrate buffer, pH 4.5, i.p.) [27].
STZ-exposed rats with blood glucose level in excess of
300 mg/dL, 3 weeks after the exposure were considered
as diabetic.
Group 4: STZ and CUR: post-treatment group: rats
received CUR (orally, 100 mg/kg body weight in olive oil)
after 3 weeks from the day on which STZ was  injected until
the 56th day.
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Fig. 1. (A) Schematic diagram of the experimental protocol. (B) Representation of the dose dependent study of CUR on ALP level in STZ-treated diabetic
pathophysiology in the serum of the experimental rats. Cont: measurement of serum ALP in normal rats, STZ: measurement of serum ALP in STZ administered
rats,  STZ + CUR 40, STZ + CUR 70, STZ + CUR 100, STZ + CUR 130 and STZ + CUR 160: measurement of serum ALP in rats which are treated with CUR at a dose
of  40 mg/kg, 70 mg/kg, 100 mg/kg, 130 mg/kg and 160 mg/kg body weight, orally, respectively, after STZ administration at a dose of 60 mg/kg body weight,
i.p.  (C) Representation of the time dependent study of CUR on ALP activity in STZ-exposed diabetic pathophysiology in the serum of the experimental rats.
Cont:  measurement of serum ALP in normal rats, STZ: measurement of serum ALP in STZ exposed rats, STZ + CUR 2 wk, STZ + CUR 4 wk, STZ + CUR 8 wk,
STZ  + CUR 12 wk and STZ + CUR 16 wk: measurement of serum ALP in rats which are treated with CUR at a dose of 100 mg/kg body weight, orally for 2















rnd  CUR on body weight of rats. “a” indicates the signiﬁcant difference b
ifference between STZ exposed (toxin control) and CUR post-treated gro
In the present study, there was another group, namely,
ehicle control group (STZ + olive oil). The animals in this
roup received STZ and after the onset of diabetes (3 weeks
rom the day on which STZ was injected), only olive oil was
iven until 56th day.
After the experimental periods animals were sacriﬁced
nd liver was collected. The experimental design for the
resent study was summarized in Fig. 1A.
.2.2. Determination of dose and time-dependent
ctivity of CUR by ALP assay
For this study, rats were randomly distributed into
even groups each consisting of six animals. The ﬁrst two
roups served as normal control (receiving vehicle only)
nd toxin control (receiving STZ at a single dose of 60 mg/kg
ody weight in citrate buffer, pH 4.5, i.p.), respectively. The
emaining ﬁve groups of animals were treated with ﬁvethe normal control and STZ exposed groups, “b” indicates the signiﬁcant
h column represents mean ± SEM, n = 6; (pa < 0.05, pb < 0.05).
different doses of CUR (40, 70, 100, 130 and 160 mg/kg body
weight) for 56 days after 3 weeks followed by STZ injection
(at a single dose of 60 mg/kg body weight in citrate buffer,
pH 4.5, i.p.).
For the time-dependent study, rats were randomly dis-
tributed into seven groups each consisting of six animals.
The ﬁrst two groups served as normal control (receiving
only vehicle) and toxin control (exposed to STZ at a sin-
gle dose of 60 mg/kg body weight in citrate buffer, pH 4.5,
i.p.), respectively. The remaining six groups of animals were
treated with CUR orally at a dose of 100 mg/kg body weight,
once daily for 2, 4, 8, 12 and 16 weeks after the onset of
diabetes, i.e., 3 weeks after STZ administration.2.2.3. Measurement of body weight
The body weights of all the experimental animals from
each group were measured.
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2.2.4. Preparation of liver tissue homogenate
Liver samples from experimental animals were ﬁrst
homogenized (1:4, w/v) in ice-cold 0.1 M phosphate buffer
(pH 7.4) containing 2 mM EDTA. Then the homogenate was
centrifuged at 10,000 × g for 30 min  at 4 ◦C. The supernatant
was collected and again centrifuged at 105,000 × g for
55 min. The resulting pellets called microsomal fractions
were suspended in 0.25 mM sucrose solution containing
1 mM EDTA and stored at −80 ◦C until use. The supernatant
was also collected and used for the experiments as the cyto-
solic fraction. The protein contents of both the cytosolic
fraction and microsomal fraction were measured by the
method of Bradford [28] using crystalline BSA as standard.
2.2.5. Determination of hepatic markers and nitric oxide
production
Speciﬁc markers related to hepatic dysfunction, e.g.,
ALT, AST, ALP activities and albumin were estimated by
using standard kits. LDH activity was determined accord-
ing to the method of Kornberg [29]. The hepatic NO level
was indirectly assessed by measuring the nitrite levels in
the cytosolic fraction by using a colorimetric method based
on the Griess reaction [30,31].
2.2.6. Estimation of lipid peroxidation
Lipid peroxidation in terms of malondialdehyde (MDA)
formation was  estimated according to the method of Ester-
bauer et al. [32].
2.2.7. Assay of cellular metabolites
GSH contents were measured, following the method
of Ellman [33], using DTNB (Ellman’s reagent) as the key
reagent.
GSSG contents were determined according to the
method of Hissin et al. [34].
2.2.8. Determination of in vivo antioxidant power by
FRAP assay
FRAP assay was performed according to the method as
described by Benzie et al. [35].
2.2.9. Assay of antioxidant enzymes
The activities of different antioxidant enzymes, SOD,
CAT, GST, GR, and GPx, have been estimated in liver tissue
homogenates. SOD activity was determined as described
previously [36]. One unit of SOD activity is deﬁned as the
enzyme concentration that required inhibiting chromogen
production by 50% in 1 min  under the assay conditions.
CAT activity was estimated by following the decompo-
sition of H2O2 at 240 nm for 10 min  and was monitored
spectrophotometrically, according to the method of
Bonaventura et al. [37]. One unit of CAT activity is described
as the amount of enzyme, which reduces one mol  of H2O2
per minute.
GST activity was assayed based on the conjugation reac-
tion with GSH in the primary step of mercapturic acid
synthesis [38]. GST activity was expressed as moles of
CDNB conjugate formed/min/mg protein.
GR activity was determined following the method of
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GPx activity was  measured according to the method of
Flohe and Gunzler [40] using H2O2 and NADPH as sub-
strates.
2.2.10. Detection of cell death pathway by ﬂow
cytometry
Hepatocytes were isolated from all the experimental
groups of rats. The animals were anaesthetized and livers
were extensively perfused in phosphate buffer saline to get
rid of blood and irrigated in a buffer [Hepes (10 mM), KCl
(3 mM),  NaCl (130 mM),  NaH2PO4–H2O (1 mM)  and glucose
(10 mM)], pH 7.4 and incubated with a second buffer con-
taining CaCl2 (5 mM),  0.05% collagenase type I and mixed
with the buffer (previously described) for ∼45 min  at 37 ◦C.
The liver sample was then passed through a wide bore
syringe, ﬁltered, centrifuged and the pellet was  suspended
in PBS. Cells were then washed with PBS, centrifuged at
800 × g for 6 min, resuspended in ice-cold 70% ethanol/PBS,
centrifuged at 800 × g for a further 6 min  and resuspended
in PBS. Cells so obtained were then incubated with propid-
ium iodide (PI) and FITC-labelled Annexin V for 30 min  at
37 ◦C. Excess PI and Annexin V were then washed off. Cells
were then ﬁxed and stained and ﬁnally analysed by ﬂow
cytometry using FACS Calibur (Becton Dickinson, Moun-
tain View, CA) equipped with 488 nm argon laser light
source; 515 nm band pass ﬁlter for FITC-ﬂuorescence and
623 nm band pass ﬁlter for PI-ﬂuorescence using CellQuest
software. A scatter plot of PI-ﬂuorescence (y-axis) vs FITC-
ﬂuorescence (x-axis) was prepared to show the effects.
2.2.11. DNA fragmentation assay
Hepatic tissue was washed with STE buffer (0.1 M NaCl,
10 mM Tris–HCl, 1 mM EDTA, pH 8) and 1 mL  homogeniza-
tion buffer (0.1 M NaCl, 0.2 M sucrose, 0.01 M EDTA, 0.3 M
Tris, pH 8), and 100 L 10% SDS was  added and mixed well
by vortexing and incubated at 65 ◦C for 1 h. 175 L of 8(M)
potassium acetate was then added and incubated in ice-
bath for 1 h, then centrifuged and the supernatant was
collected. Equal volume of phenol–chloroform solution
was  added, mixed thoroughly and centrifuged to separate
phases. The upper-most layer was taken in a fresh cen-
trifuge tube. Equal volume of chloroform was added and
centrifuged. The aqueous layer was taken in a fresh tube.
1/10th vol. of 3(M) sodium acetate (pH 7.4) and 2.5 times
the volume of ethanol were added and centrifuged. The
precipitated DNA was  washed with 80% ethanol. The DNA
fragmentation was assayed by electrophoresing genomic
DNA samples on agarose/EtBr gel.
2.2.12. Determination of mitochondrial membrane
potential ( m)
Mitochondria were isolated following the method of
Hodarnau et al. [41]. The membrane potential ( m)
was  measured using a FACS scan ﬂow cytometer with an
argon laser excitation at 488 and 525 nm band pass ﬁlter.
The evaluation of the mitochondrial membrane potential
( m) was determined on the basis of cell preservation of
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.2.13. Immunoblotting
Proteins (50 g) from each sample were separated by
0% SDS-PAGE and transferred into PVDF membranes.
embranes were then blocked using BSA and incubated
eparately with primary antibodies of anti caspase-3, anti-
53, anti-PARP and anti-Bcl-xL (1:1000 dilution), anti
ytochrome c (1:1000 dilution), anti Bad (1:1000 dilution),
nti Bax (1:1000 dilution), anti Bcl-2 (1:1000 dilution),
nti p-38 (1:1000 dilution) and anti ERK1/2 (1:1000 dilu-
ion) at 4 ◦C for overnight. The membranes were washed
n TBST (50 mmol/L Tris–HCl, pH 7.6, 150 mmol/L NaCl,
.1% Tween 20) for ∼30 min  and incubated with appropri-
te HRP conjugated secondary antibody (1:2000 dilution)
or 2 h at room temperature and developed by the HRP
ubstrate 3,3′-diaminobenzidine tetrahydrochloride (DAB)
ystem (Bangalore, India).
.2.14. Histological studies
Livers from the normal and experimental rats were
xed in 10% buffered formalin and were processed for
arafﬁn sectioning. Sections of about 5 m thickness were
tained with haematoxylin and eosin to evaluate under
ight microscope. Mean values were calculated from each
f six glomeruli per section.
.2.15. Statistical analysis
All experimental values have been represented as
ean ± SEM (n = 6). Data on biochemical investigation
ere analysed using analysis of variance (ANOVA) and the
roup means were compared by Tukey’s test. p-Values of
.05 or less were considered signiﬁcant.
. Results and discussions
.1. STZ induced diabetic models
STZ induced experimental diabetes is an example of
hemically induced diabetes model. This model has some
dvantages [45] like selective loss of pancreatic beta cells
eaving other pancreatic cells (alpha and delta) intact;
ess ketosis and related mortality. Besides, residual insulin
ecretion permits the animals to live long period of time
ithout insulin treatment. In addition, this model is rela-
ively cost effective, easy to develop and maintain. In spite
f these advantages, there are some limitations [45] also.
irstly, hyperglycaemia is developed primarily by the direct
ytotoxic effects of STZ on the beta cells and insulin deﬁ-
iency rather than consequences of insulin resistance, i.e.,
t is hard to extrapolate the outcomes from any study to
ype II diabetes. Moreover, STZ induced diabetes has been
bserved to be less stable and reversible in many cases;
ainly because of the spontaneous regeneration of beta
ells. Hence, we had to check the blood glucose levels
eriodically during the experiments. In addition, STZ may
roduce some toxic actions on other body organs as well
n spite of its cytotoxic action on beta cells. There may  be
nother problem of variability of results in this model.While the single high dose injection of STZ can pro-
uce type I diabetes in adult rats, STZ, when injected at
he neonatal stage or immediately after birth, can lead to
ype II diabetes at the adult age. The neonatal STZ exposedrts 2 (2015) 365–376 369
rats are considered ([43,44]) to be better model for the elu-
cidation of the mechanisms associated with regeneration
of the beta cells, the functional exhaustion of the beta cells
and the emergence of defects in insulin action.
Recently, a novel type 2 diabetic rat model ([46]) has
been introduced by the combination of short term high fat
diet (HFD) feeding followed by low dose of STZ (35 mg/kg,
i.p.) treatment. It is unique as the dose of STZ selected
causes diabetes only in HFD-fed insulin resistant rats where
as it fails to induce the same in normal control rats reﬂect-
ing the actual situation in humans with risk factors of
obesity and insulin resistance.
3.2. Dose and time-dependent effect of CUR on
STZ-induced hepatotoxicity
STZ induces experimental diabetes in rats [47], thereby
produces hepatotoxicity and elevates the activities of
serum marker enzymes (ALT, ALP, etc.). So, we performed
a dose-dependent study using ALP assay as an index of
STZ mediated hepatic damage to determine the optimum
dose and time for CUR treatment. The result of our study
suggests that STZ at a dose of 60 mg/kg body weight up-
regulated the ALP activity in serum although that could
be reversed with the treatment of CUR up to a dose of
100 mg/kg body weight (Fig. 1B and C). Similarly time
dependent study provided the optimum time of 8 weeks
(56 days) for CUR treatment for maximum beneﬁcial effect
against STZ exposure. Effect of CUR was  not much beyond
this concentration or time period respectively. There-
fore, after 3 weeks of STZ administration, 100 mg/kg body
weight of CUR for 56 days (once, daily) was  chosen as the
optimum dose and time for the post-treatment study.
The beneﬁcial effects of curcumin are mainly limited
due to its poor pharmacokinetics and pharmacodynamics,
i.e., short half-life, poor absorption and rapid metabolism
in the GI tract. For this reason, daily intake level of
0.1–3 mg/kg-BW of curcumin has been considered as an
acceptable dose by the Joint FAO/WHO Expert Committee
on Food Additives, 1996 [48]. Moreover, turmeric is Gen-
erally Recognized As Safe (GRAS) by the US FDA.
Moreover, the doses administered in clinical trials are
generally expected to be rather higher than those nor-
mally consumed in the diet. A good number of studies have
been performed as well. In such a preclinical study involv-
ing the administration of 2% dietary curcumin (approx.
1200 mg/kg-BW) to rats for 14 days [16] or in a study
involving the administration of 0.2% dietary curcumin
(approx. 300 mg/kg-BW) to mice for 14 weeks, no toxicity
was observed [49].
A study on the uptake and bio-distribution of dietary
curcumin in rodents suggests that after ingestion orally,
peak serum levels of curcumin are low [50]. In these stud-
ies, the dose of 2 g/kg resulted in 1.35 g/mL peak serum
levels [51]. In humans, a daily dose of 4–8 g resulted in
peak serum levels of 0.4–3.6 M after 1 h. In India, where
the average intake of turmeric may  reach the level of
2000–2500 mg  per day (corresponding to approx. up to
100 mg  of curcumin), no toxicities or adverse effects have
been reported at the population level [52]. In another study
in Taiwan, Cheng et al.,  showed that the administration
370 S. Ghosh et al. / Toxicology Reports 2 (2015) 365–376
Table 1
Liver biomarker-enzyme activities.
Parameters NOR CUR STZ STZ + CUR
LDHd 175.99 ± 1.89 198.37 ± 2.12 467.58 ± 3.58a 253.51 ± 2.73b
ALPe 15.79 ± 1.35 18.37 ± 1.93 42.69 ± 2.47a 24.25 ± 3.01b
ALTf 60.92 ± 1.41 69.54 ± 2.14 148.75 ± 2.17a 81.02 ± 2.43b
ASTf 142.31 ± 4.13 159.67 ± 3.82 353.33 ± 6.50a 215.86 ± 7.69b
Albuming 3.55 ± 0.07 3.46 ± 0.08 2.25 ± 0.10a 3.10 ± 0.09b
Blood glucoseh 105 ± 9 98 ± 7 385 ± 13a 203 ± 14b
a “a” values differs signiﬁcantly from normal control (pa < 0.05).






of high-dose of oral curcumin (500, 1000, 2000, 4000,
and 8000 mg  of curcumin daily) for 3 months showed
no noticeable adverse effects [53]. Phase I clinical trials
have demonstrated that curcumin is safe even at a dose
of 12 g/day in humans but exhibit relatively poor bioavail-
ability [50].
To overcome this problem associated with bioavail-
ability of curcumin, numerous approaches have been
undertaken. These approaches include the use of adju-
vant like piperine (interferes with glucuronidation); the
use of liposomal curcumin; administration of curcumin
nanoparticles and the use of curcumin phospholipid com-
plex, etc. [54–56]. Moreover, no signiﬁcant difference was
observed between the results obtained from “STZ” group
and “STZ + olive oil” (vehicle control) group (data not
shown).
3.3. Body weight
Our studies showed physical lethargy in the STZ
exposed rats in the early days of the experiment and these
animals gained less body weight compared to controls
(Fig. 1D). CUR treatment, however, given protection against
this type of deﬁciency suggesting the growth-inhibiting




Parameters NOR CUR 
SODc 178.94 ± 5.87 164.65 ± 6
CATd 131.89 ± 3.34 122.77 ± 4
GSTe 3.29 ± 0.12 2.96 ± 0
GRf 120.57 ± 2.33 111.24 ± 3
GPxg 130.64 ± 4.84 122.47 ± 4
MDAh 1.15 ± 0.04 1.53 ± 0
NO productioni 37.15 ± 1.04 42.53 ± 1
a “a” values differs signiﬁcantly from normal control (pa < 0.05).







i mM.3.4. Effect of CUR on biochemical parameters
3.4.1. Effect on ALT, ALP, AST, albumin, LDH and NO levels
Single oral dose of STZ (60 mg/kg body weight) induced
diabetes which signiﬁcantly increased liver damage, as
evidenced by a dramatic elevation of serum ALT, AST, ALP
and LDH activities in STZ exposed group (Table 1). Results
suggested that transport function and membrane perme-
ability have been altered due to the liver injury, leading to
leakage of these enzymes. The activities of those hepato-
toxicity markers in CUR treated group remained almost the
same as normal. In the CUR post treated group, those mark-
ers’ activities were signiﬁcantly decreased towards normal,
i.e., CUR protected liver (hepatocytes) from diabetic patho-
physiology. The level of albumin was  also decreased in STZ
exposed group and shifted towards the normal value by
CUR post treatment.
NO level was also increased signiﬁcantly in STZ exposed
animals (Table 2). As STZ is a nitric oxide (NO) donor and NO
has been found to bring about the destruction of pancre-
atic islet cells, it is assumed that this molecule contributes
to STZ-induced DNA damage [57,58]. The participation of
NO in exerting the cytotoxic effect of STZ was conﬁrmed
in other experiments also [59]. Moreover, increased NO
production as a result of the diabetic pathophysiology
was  responsible for both cell apoptosis and necrosis when
NO interacts with superoxide anion to form peroxynitrite.
STZ STZ + CUR
.20 131.43 ± 6.06a 159.45 ± 7.01b
.25 68.35 ± 4.57a 112.04 ± 6.41b
.04 1.16 ± 0.01a 2.59 ± 0.08b
.35 65.33 ± 3.58a 103.93 ± 5.74b
.92 54.57 ± 3.85a 106.20 ± 5.71b
.05 4.05 ± 0.06a 2.17 ± 0.04b
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owever, post-treatment with CUR effectively reduced
hese alterations and ameliorated hepatocytes from dia-
etic pathophysiology as evidenced from the results.
.4.2. Effect on lipid peroxidation
Lipid peroxidation gives an indication of cellular injury
ediated by reactive oxygen species [60] with the con-
omitant destruction of membrane lipids and thereby
roduction of lipid peroxides. The present study showed
hat STZ exposure signiﬁcantly enhanced hepatic lipid per-
xidation in the experimental animals compared to normal
nd only CUR treated animals. It was also seen that CUR
dministration signiﬁcantly inhibited hepatic lipid peroxi-
ation (Table 2).
.4.3. Effect on cellular GSH and GSSG levels
Glutathione (GSH) is a cysteine-containing peptide
ound in almost all forms of aerobic life [61]. It is syn-
hesized within the cells from its constituent amino acids.
SH shows antioxidant activities due to the presence of
 thiol group in its cysteine moiety; acting as a reducing
gent that can be reversibly oxidized and reduced [62].
ig. 2. (A) Measurement of cellular levels of GSH. (B) Measurement of cellular lev
ifference between the normal control and STZ exposed groups, “b” indicates t
ost-treated groups. Each column represents mean ± SEM, n = 6 (pa < 0.05, pb < 0.0rts 2 (2015) 365–376 371
GSH plays an important role in maintaining cellular antiox-
idant capacity. So we  measured GSH levels and found that
STZ exposure resulted in rapid depletion of hepatic GSH,
thereby decreasing the GSH/GSSG ratio in case of STZ group
compared to normal. GSH levels remained almost the same
as normal in the only CUR treated group as expected (Fig. 2A
and B).
3.4.4. Effect on ferric reducing antioxidant power (FRAP)
Ferric reducing antioxidant power (FRAP) assay is per-
formed to determine the antioxidant capacity [35]. We
have performed FRAP assay to evaluate the antioxidant
capacity of the hepatic tissues of different groups and
observed that STZ induced diabetic pathophysiology also
caused a signiﬁcant reduction in FRAP value (Table 1) in STZ
exposed group compared to normal and only CUR treated
group. However, CUR treatment restored the FRAP value
towards normal (Fig. 2C).3.4.5. Effect on cellular antioxidant enzymes
Cellular antioxidant enzymes are one of the most
directly acting molecules that counteract oxidative burst
els of GSSG. (C) Measurement of FRAP values. “a” indicates the signiﬁcant
he signiﬁcant difference between STZ exposed (toxin control) and CUR
5).
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Fig. 3. (A) DNA fragmentation pattern on agarose/EtBr gel. Lane 1 marker (1 kb DNA ladder), lanes 2, 3, 4 and 5 DNA isolated from normal, CUR treated, STZ
administered, CUR post treated rats, respectively. Arrows indicate ladder formation. CUR decreased all the STZ-induced pro-apoptotic events in hepatic
tissue.  (B) Measurement of apoptosis in hepatocytes by the use of ﬂow cytometry analysis. Percent distribution of apoptotic and necrotic hepatocytes
 The FIT
he six inshown. Cell distribution analysed using Annexin V binding and PI uptake.
ﬁlters, respectively. Results expressed as dot plot representing as one of t
no matter how that is generated in the system. So we  have
also examined the activities of antioxidant enzymes like
SOD, CAT, GST, GR and GPx in the present study. Results
showed that STZ decreased the antioxidant enzyme activi-
ties in the hepatic tissues (Table 2) and CUR administration
restored those enzyme activities towards the normal value.
Together these results imply that CUR protected rat liver
against STZ-induced diabetic pathophysiology mainly by
exerting its antioxidant properties.
3.5. STZ-induced hepatocellular apoptosis
To investigate the mode of cell death, we have done
ﬂuorescence-activated cell-sorting (FACS) and DNA gel
electrophoresis to identify the nature of cellular death
(necrosis and/or apoptosis) in the liver. DNA isolated
from STZ-exposed rats showed mainly ladder (a hallmark
of apoptosis) on the agarose gel (Fig. 3A). Again, from
ﬂow-cytometric data we found that, hepatocytes isolated
from STZ-exposed rats showed maximum Annexin V-FITC-
binding compared to control untreated hepatocytes, but
very little PI staining, indicating the majority of cells under-
went apoptosis (Fig. 3B). Therefore, cross-checked with
Annexin V/PI staining also support the apoptotic cell death
in this pathophysiology. However, CUR administration
showed a satisfactory level of improvement in hepato-
cytes viability in both the cases, there by suggesting the
protective efﬁcacy along with the anti-apoptotic nature of
CUR.
3.6. Effect of CUR on hepatic histologyHistological assessments of different liver segments of
the normal and experimentally treated animals have been
presented in (Fig. 4B). STZ administration induced liver tis-
sue damage along the central vein and disorganized theC and PI ﬂuorescence measured using ﬂow cytometer with FL-1 and FL-2
dependent experiments. The measurements were performed six times.
normal radiating pattern of cell plates around it. How-
ever, CUR treatment showed a considerable improvement
in liver morphology.
3.7. Effect of CUR on molecular signalling pathways
Our next goal in the present study was  to explore the
plausible molecular signalling pathways through which
CUR exerted its ameliorative actions in diabetes-induced
hepatic pathophysiology.
3.7.1. Effect on p53 activation
The tumour suppressor protein p53 is a stress-
responsive protein and it plays a critical role in regulating
both cell survival and death depending on the cell type and
nature of stress involved [63]. A number of earlier studies
reported that p53 plays a central role in diabetic patho-
physiology in various organs like heart [1,64,65], pancreas
[66], kidney [67,68], etc. So, in this study we wanted to
investigate the possible role of p53 in hepatic tissue and
measured the protein level using immunoblot assay. We
found that STZ exposure signiﬁcantly increased p53 protein
levels (Fig. 5A) and CUR attenuated this activation. So it can
be concluded that STZ exposure could effectively induce
p53 activation, and subsequent hepatic cellular death in a
p53-dependent manner which is ameliorated by using CUR.
3.7.2. Effect on MAPKs activation
Earlier reports suggest that oxidative stress induces
MAPK family proteins [69]. Among the members of this
protein family, p38 and ERK1/2 MAPKs play crucial roles
in STZ-induced cell death pathways [70]. Besides, these
proteins also play important roles in maintaining nuclear
response to stress and cell survival [71]. So, we inves-
tigated whether p38 and ERK1/2 MAPKs have any role
in the present scenario of organ pathophysiology. Results
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Fig. 4. (A) Measurement of the mitochondrial membrane potential by ﬂow cytometry analysis (using JC-1) from liver tissue homogenates. (B) Studies
on  histological assessments; haematoxylin and eosin stained liver section of (A) normal rat liver (×100), (B) CUR treated liver section (×100), (C) STZ

































tntoxicated liver section (×100) and (D) CUR treated after STZ intoxicated
ompared to the normal liver section.
f immunoblot analysis showed that STZ-exposure did
timulate p38 and ERK1/2 MAPKs phosphorylation (Fig. 5A)
n the hepatic tissue and this effect was signiﬁcantly
eversed by CUR treatment, suggesting that CUR attenuates
TZ-induced cell death by inhibiting MAPKs activation.
In healthy cells, Bax, a proapoptotic member of the
cl-2 protein family, is present in the cytosol. Under stress-
ng condition, Bax undergoes a conformational change and
ranslocated into the mitochondria from cytosol and causes
amages to the outer mitochondrial membrane causing
itochondrial membrane depolarisation and subsequent
elease of cytochrome c into the cytosol. These sequences
f events were experimentally observed in our present
tudy by immunoblot assay of cytochrome c (Fig. 5A).
lthough earlier reports [72,73] suggest that p53 stimu-
ates the mitochondrial cell death pathway, our ﬁndings in
his study clearly suggest that p38 and ERK1/2 MAPKs also
nitiate the same apoptotic pathway.
.7.3. Effect on mitochondrial membrane potential
 m)
Maintenance of mitochondrial membrane potential
 m) is fundamental for cellular survival and loss of it
 m) may  induce a cascade of reactions leading to cellu-
ar apoptosis [74]. Disruption of mitochondrial membrane
otential ( m) induces the release of cytochrome c into
he cytosol and activates downstream apoptotic signalling
athways [75]. Results of our present study showed
hat STZ induced diabetic pathophysiology reduced the
itochondrial membrane potential signiﬁcantly and CUR
ould ameliorate this event effectively (Fig. 4A). Our
mmunoblotting studies showed that cytosolic cytochrome
 level was increased in STZ exposed group compared
o normal as in the case of (Fig. 5A) the transloca-
ion of Bax from cytoplasm to mitochondria. In both theection (×100). Arrows indicate centrilobular apoptosis in the liver tissue
cases immunoblot assay also showed that CUR post treat-
ment could effectively ameliorate these two apoptotic
phenomena.
3.7.4. Effect on caspase 3 activation and PARP cleavage
Following the release into the cytosol, cytochrome c
induces the formation of apoptosomes which in turn acti-
vates caspase 9 and other downstream caspases [76]. In
our study, occurrence of apoptosis was determined by
caspase-3 activation and PARP cleavage. The cellular level
of cleaved caspase 3, a product and indicator of caspase-3
activation and subsequent apoptosis [77], was  signiﬁcantly
increased in STZ-exposed hepatocytes; however, normalcy
was restored in CUR post-treated group. As expected, only
CUR group showed no such indication of caspase 3 acti-
vation. We  have also measured the level of PARP, the
substrate of cleaved caspase 3. Immunoblot study showed
signiﬁcant enhancement of PARP (116 kDa) cleavage in STZ
exposed group into the 89 kDa fragment although there
was almost no such PARP cleavage observed in any other
group (Fig. 5B).
In short, these results indicate that CUR might be a pro-
tective dietary antioxidant molecule that could effectively
ameliorate all the adverse effects of STZ-induced hepatic
pathophysiology by inhibiting p53 and p38-ERK1/2 MAPKs
mediated mitochondrial Bax translocation and subsequent
intrinsic mitochondrial apoptotic pathway.
3.7.5. Effect on pro and anti-apoptotic protein levels
To further conﬁrm our ﬁndings we have also mea-
sured the expression levels of anti-apoptotic proteins
Bcl-2 and Bcl-xL and pro-apoptotic protein Bad. Both
type of the proteins (pro and anti) together control the
antiapoptotic–apoptotic nature of cells. In our study we
observed (Fig. 5A) a marked decrease in the expression
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Fig. 5. (A) Western blot analysis of different proteins such as p53, total and phospho ERK1/2, total and phospho p38, Bax, Bcl-2, Bcl-xL and cytochrome c.
-Actin served as a loading control. “a” indicates the signiﬁcant difference between the normal and STZ-exposed rat liver tissue homogenates, “b” indicates
the  signiﬁcant difference between STZ and CUR + STZ-treated liver tissue homogenates. Each column represents mean ± SEM, n = 6 (pa < 0.05, pb < 0.05). (B)
Western blot analysis depicting the ultimate effects of CUR on STZ exposed mouse liver; caspase-3 activation and PARP cleavage in rat liver. -Actin served
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evel of the Bcl-2 and Bcl-xL in the STZ exposed group,
hereas no such decrease was observed in the CUR treated
roup or normal. The expression level of Bad, however,
howed opposite phenomenon.
. Conclusion
In summary, our study indicates that STZ induces dia-
etic pathophysiology and thereby generation of oxidative
tress that leads to systematic apoptosis within liver via
he activation of p38-ERK1/2 and p53-mediated molec-
lar signalling pathways. In this circumstance, CUR, a
ell-known antioxidant, might protect liver (hepatocytes)
rimarily by two ways: ﬁrstly, it offers protection by ele-
ating the antioxidant enzyme activities and scavenging
OS as evident from biochemical results and secondly,
t plays the same ameliorative role by the inhibition of
hosphorylations of p38, ERK1/2 MAPKs, subsequent Bax
ranslocation to mitochondria and mitochondrial perme-
bilization. So we are hopeful about the promising solution
f diabetes-induced liver tissue apoptosis using curcumin
aving no known adverse effect so far.
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